Fulgent Q3 2026: Revenue Growth Slows, Losses Widen, Undermining Cash-Backed Thesis

What happened

Fulgent Genetics reported third-quarter 2026 revenue of $90.4 million, up just 7.5% year-over-year, a sharp deceleration from the mid-teens growth the company had sustained through 2025. GAAP net loss widened to $13.2 million, or $0.48 per share, while non-GAAP loss of $2.4 million and adjusted EBITDA loss of $7.5 million reversed the modest profitability seen a year earlier. The results indicate that the diagnostics franchise is struggling to maintain volume and pricing momentum, likely impacted by customer concentration and competitive pressures. The operating losses, combined with ongoing therapeutics spending, will accelerate cash burn and erode the balance-sheet cushion that previously anchored the investment case. Management's previous base case of 12–15% growth and breakeven EBITDA for 2026 now appears unlikely without a significant turnaround in the fourth quarter.

Implication

The investment thesis that FLGT's cash balance provided a floor below the stock price is now under threat because operating losses are consuming that cash at an accelerating pace. With adjusted EBITDA at negative $7.5 million in a single quarter and revenue growth below 8%, the company is trending toward the bear scenario outlined in the master report. The market may begin to value the therapeutics segment as a cash drain rather than an option, and the customer concentration risk becomes more acute if the large client is driving the slowdown. Unless management can demonstrate a credible path to cost reduction or growth reacceleration, the stock is likely to trade below its cash per share as investors discount the burn. We would downgrade the rating from Potential Buy to Neutral and await concrete evidence of operating leverage before considering re-entry.

Thesis delta

The original thesis assumed the diagnostics business would sustain mid-teens growth and approach breakeven, making the stock a cash-backed value play. The Q3 2026 results show growth has halved and the business has swung to a meaningful EBITDA loss, breaking the base case. The thesis shifts to a more cautious stance: the margin of safety from cash is shrinking and the stock may no longer offer asymmetric upside; we downgrade to neutral and require proof of cost discipline and revenue recovery.